NCT06692166 2024-11-22
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3 Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Celldex Therapeutics